

Chee Man Cheong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4442750/publications.pdf>

Version: 2024-02-01

9
papers

369
citations

1478505

6
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

715
citing authors

#	ARTICLE	IF	CITATIONS
1	N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. <i>BMC Cancer</i> , 2018, 18, 939.	2.6	222
2	HIF-2 α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1. <i>Cancer Research</i> , 2017, 77, 5452-5463.	0.9	41
3	Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. <i>Experimental Cell Research</i> , 2015, 332, 24-38.	2.6	31
4	Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 387-399.	2.5	25
5	Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. <i>Cancer Letters</i> , 2020, 475, 99-108.	7.2	22
6	Barrier-to-autointegration-factor (Baf1) modulates DNA double-strand break repair pathway choice via regulation of DNA-dependent kinase (DNA-PK) activity. <i>Nucleic Acids Research</i> , 2021, 49, 3294-3307.	14.5	13
7	The Impact of Rare Human Variants on Barrier-To-Auto-Integration Factor 1 (Baf1) Structure and Function. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 775441.	3.7	8
8	LCRF0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH1, synergistically increases multiple myeloma response to bortezomib. <i>FASEB BioAdvances</i> , 2020, 2, 339-353.	2.4	6
9	Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. <i>Blood</i> , 2014, 124, 647-647.	1.4	1